» Articles » PMID: 22235232

Comprehensive Evidence-based Assessment and Prioritization of Potential Antidiabetic Medicinal Plants: a Case Study from Canadian Eastern James Bay Cree Traditional Medicine

Abstract

Canadian Aboriginals, like others globally, suffer from disproportionately high rates of diabetes. A comprehensive evidence-based approach was therefore developed to study potential antidiabetic medicinal plants stemming from Canadian Aboriginal Traditional Medicine to provide culturally adapted complementary and alternative treatment options. Key elements of pathophysiology of diabetes and of related contemporary drug therapy are presented to highlight relevant cellular and molecular targets for medicinal plants. Potential antidiabetic plants were identified using a novel ethnobotanical method based on a set of diabetes symptoms. The most promising species were screened for primary (glucose-lowering) and secondary (toxicity, drug interactions, complications) antidiabetic activity by using a comprehensive platform of in vitro cell-based and cell-free bioassays. The most active species were studied further for their mechanism of action and their active principles identified though bioassay-guided fractionation. Biological activity of key species was confirmed in animal models of diabetes. These in vitro and in vivo findings are the basis for evidence-based prioritization of antidiabetic plants. In parallel, plants were also prioritized by Cree Elders and healers according to their Traditional Medicine paradigm. This case study highlights the convergence of modern science and Traditional Medicine while providing a model that can be adapted to other Aboriginal realities worldwide.

Citing Articles

A Multivariate Approach to Ethnopharmacology: Antidiabetic Plants of Eeyou Istchee.

Hall B, Rapinski M, Spoor D, Eid H, Saleem A, Arnason J Front Pharmacol. 2022; 12:511078.

PMID: 35126097 PMC: 8808167. DOI: 10.3389/fphar.2021.511078.


Barriers and Mitigating Strategies to Healthcare Access in Indigenous Communities of Canada: A Narrative Review.

Nguyen N, Subhan F, Williams K, Chan C Healthcare (Basel). 2020; 8(2).

PMID: 32357396 PMC: 7349010. DOI: 10.3390/healthcare8020112.


Understanding glycaemic control and current approaches for screening antidiabetic natural products from evidence-based medicinal plants.

Lankatillake C, Huynh T, Dias D Plant Methods. 2019; 15:105.

PMID: 31516543 PMC: 6731622. DOI: 10.1186/s13007-019-0487-8.


Anti-apoptotic potential of several antidiabetic medicinal plants of the eastern James Bay Cree pharmacopeia in cultured kidney cells.

Li S, Pasquin S, Eid H, Gauchat J, Saleem A, Haddad P BMC Complement Altern Med. 2018; 18(1):37.

PMID: 29378549 PMC: 5789738. DOI: 10.1186/s12906-018-2104-1.


Diabetes mellitus and the Aboriginal diabetic initiative in Canada: An update review.

Leung L J Family Med Prim Care. 2016; 5(2):259-265.

PMID: 27843824 PMC: 5084544. DOI: 10.4103/2249-4863.192362.


References
1.
Wajngot A, Chandramouli V, Schumann W, Ekberg K, Jones P, Efendic S . Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus. Metabolism. 2001; 50(1):47-52. DOI: 10.1053/meta.2001.19422. View

2.
Harrigan R, Nathan M, Beattie P . Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med. 2001; 38(1):68-78. DOI: 10.1067/mem.2001.114314. View

3.
Wu C, Okar D, Kang J, Lange A . Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes. Curr Drug Targets Immune Endocr Metabol Disord. 2005; 5(1):51-9. DOI: 10.2174/1568008053174769. View

4.
LOUBATIERES A . [The discovery of hypoglycemic sulfonamides and particularly of their action mechanism]. Acta Diabetol Lat. 1969; 6 Suppl 1:20-56. View

5.
Riddle M . Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am. 2005; 34(1):77-98. DOI: 10.1016/j.ecl.2004.12.002. View